Logo image of 1JNJ.MI

JOHNSON & JOHNSON (1JNJ.MI) Stock Fundamental Analysis

Europe - BIT:1JNJ - US4781601046 - Common Stock

165.22 EUR
+0.42 (+0.25%)
Last: 10/20/2025, 7:00:00 PM
Fundamental Rating

5

1JNJ gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 53 industry peers in the Pharmaceuticals industry. 1JNJ has only an average score on both its financial health and profitability. 1JNJ is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

In the past year 1JNJ was profitable.
In the past year 1JNJ had a positive cash flow from operations.
Each year in the past 5 years 1JNJ has been profitable.
1JNJ had a positive operating cash flow in each of the past 5 years.
1JNJ.MI Yearly Net Income VS EBIT VS OCF VS FCF1JNJ.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

1.2 Ratios

1JNJ has a better Return On Assets (11.72%) than 79.25% of its industry peers.
1JNJ has a better Return On Equity (28.88%) than 75.47% of its industry peers.
1JNJ's Return On Invested Capital of 13.62% is fine compared to the rest of the industry. 1JNJ outperforms 62.26% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for 1JNJ is in line with the industry average of 15.19%.
Industry RankSector Rank
ROA 11.72%
ROE 28.88%
ROIC 13.62%
ROA(3y)12.79%
ROA(5y)11.65%
ROE(3y)31.38%
ROE(5y)29.12%
ROIC(3y)15.41%
ROIC(5y)14.48%
1JNJ.MI Yearly ROA, ROE, ROIC1JNJ.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

1.3 Margins

With an excellent Profit Margin value of 25.00%, 1JNJ belongs to the best of the industry, outperforming 84.91% of the companies in the same industry.
In the last couple of years the Profit Margin of 1JNJ has declined.
1JNJ's Operating Margin of 25.69% is fine compared to the rest of the industry. 1JNJ outperforms 66.04% of its industry peers.
1JNJ's Operating Margin has improved in the last couple of years.
1JNJ's Gross Margin of 67.97% is in line compared to the rest of the industry. 1JNJ outperforms 47.17% of its industry peers.
In the last couple of years the Gross Margin of 1JNJ has remained more or less at the same level.
Industry RankSector Rank
OM 25.69%
PM (TTM) 25%
GM 67.97%
OM growth 3Y0.33%
OM growth 5Y3.14%
PM growth 3Y-15.79%
PM growth 5Y-2.98%
GM growth 3Y-0.56%
GM growth 5Y0.76%
1JNJ.MI Yearly Profit, Operating, Gross Margins1JNJ.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

5

2. Health

2.1 Basic Checks

1JNJ has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, 1JNJ has about the same amount of shares outstanding.
The number of shares outstanding for 1JNJ has been reduced compared to 5 years ago.
The debt/assets ratio for 1JNJ is higher compared to a year ago.
1JNJ.MI Yearly Shares Outstanding1JNJ.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B
1JNJ.MI Yearly Total Debt VS Total Assets1JNJ.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50B 100B 150B

2.2 Solvency

1JNJ has an Altman-Z score of 4.48. This indicates that 1JNJ is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.48, 1JNJ is in the better half of the industry, outperforming 64.15% of the companies in the same industry.
The Debt to FCF ratio of 1JNJ is 2.74, which is a good value as it means it would take 1JNJ, 2.74 years of fcf income to pay off all of its debts.
1JNJ has a better Debt to FCF ratio (2.74) than 67.92% of its industry peers.
1JNJ has a Debt/Equity ratio of 0.61. This is a neutral value indicating 1JNJ is somewhat dependend on debt financing.
1JNJ has a Debt to Equity ratio (0.61) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF 2.74
Altman-Z 4.48
ROIC/WACC1.49
WACC9.14%
1JNJ.MI Yearly LT Debt VS Equity VS FCF1JNJ.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B

2.3 Liquidity

A Current Ratio of 1.01 indicates that 1JNJ should not have too much problems paying its short term obligations.
1JNJ has a worse Current ratio (1.01) than 69.81% of its industry peers.
A Quick Ratio of 0.76 indicates that 1JNJ may have some problems paying its short term obligations.
The Quick ratio of 1JNJ (0.76) is worse than 67.92% of its industry peers.
Industry RankSector Rank
Current Ratio 1.01
Quick Ratio 0.76
1JNJ.MI Yearly Current Assets VS Current Liabilites1JNJ.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B

4

3. Growth

3.1 Past

1JNJ shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.37%.
1JNJ shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.85% yearly.
Looking at the last year, 1JNJ shows a small growth in Revenue. The Revenue has grown by 5.08% in the last year.
The Revenue has been growing slightly by 1.60% on average over the past years.
EPS 1Y (TTM)1.37%
EPS 3Y0.64%
EPS 5Y2.85%
EPS Q2Q%15.7%
Revenue 1Y (TTM)5.08%
Revenue growth 3Y4.1%
Revenue growth 5Y1.6%
Sales Q2Q%6.77%

3.2 Future

Based on estimates for the next years, 1JNJ will show a small growth in Earnings Per Share. The EPS will grow by 6.91% on average per year.
Based on estimates for the next years, 1JNJ will show a small growth in Revenue. The Revenue will grow by 4.82% on average per year.
EPS Next Y9.8%
EPS Next 2Y7.17%
EPS Next 3Y6.91%
EPS Next 5Y6.91%
Revenue Next Year5.23%
Revenue Next 2Y4.92%
Revenue Next 3Y4.88%
Revenue Next 5Y4.82%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
1JNJ.MI Yearly Revenue VS Estimates1JNJ.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20B 40B 60B 80B 100B
1JNJ.MI Yearly EPS VS Estimates1JNJ.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15

3

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 18.48, the valuation of 1JNJ can be described as rather expensive.
1JNJ's Price/Earnings is on the same level as the industry average.
When comparing the Price/Earnings ratio of 1JNJ to the average of the S&P500 Index (27.57), we can say 1JNJ is valued slightly cheaper.
A Price/Forward Earnings ratio of 16.72 indicates a correct valuation of 1JNJ.
1JNJ's Price/Forward Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.09, 1JNJ is valued a bit cheaper.
Industry RankSector Rank
PE 18.48
Fwd PE 16.72
1JNJ.MI Price Earnings VS Forward Price Earnings1JNJ.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1JNJ is on the same level as its industry peers.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of 1JNJ is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 24.9
EV/EBITDA 15.43
1JNJ.MI Per share data1JNJ.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 1JNJ does not grow enough to justify the current Price/Earnings ratio.
1JNJ has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.89
PEG (5Y)6.48
EPS Next 2Y7.17%
EPS Next 3Y6.91%

4

5. Dividend

5.1 Amount

1JNJ has a Yearly Dividend Yield of 2.71%.
1JNJ's Dividend Yield is a higher than the industry average which is at 3.00.
Compared to an average S&P500 Dividend Yield of 2.32, 1JNJ has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 2.71%

5.2 History

On average, the dividend of 1JNJ grows each year by 9.24%, which is quite nice.
Dividend Growth(5Y)9.24%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

1JNJ pays out 53.34% of its income as dividend. This is a bit on the high side, but may be sustainable.
1JNJ's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP53.34%
EPS Next 2Y7.17%
EPS Next 3Y6.91%
1JNJ.MI Yearly Income VS Free CF VS Dividend1JNJ.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B
1JNJ.MI Dividend Payout.1JNJ.MI Dividend Payout, showing the Payout Ratio.1JNJ.MI Dividend Payout.PayoutRetained Earnings

JOHNSON & JOHNSON

BIT:1JNJ (10/20/2025, 7:00:00 PM)

165.22

+0.42 (+0.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-14 2025-10-14/bmo
Earnings (Next)01-21 2026-01-21/amc
Inst Owners74.46%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap397.91B
Revenue(TTM)92.15B
Net Income(TTM)22.66B
Analysts74.84
Price Target156.97 (-4.99%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.71%
Yearly Dividend4.21
Dividend Growth(5Y)9.24%
DP53.34%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.13%
Min EPS beat(2)2.3%
Max EPS beat(2)5.96%
EPS beat(4)4
Avg EPS beat(4)4.31%
Min EPS beat(4)0.68%
Max EPS beat(4)8.28%
EPS beat(8)7
Avg EPS beat(8)3.3%
EPS beat(12)11
Avg EPS beat(12)3.74%
EPS beat(16)14
Avg EPS beat(16)3.64%
Revenue beat(2)2
Avg Revenue beat(2)1.73%
Min Revenue beat(2)0.53%
Max Revenue beat(2)2.92%
Revenue beat(4)3
Avg Revenue beat(4)0.82%
Min Revenue beat(4)-0.55%
Max Revenue beat(4)2.92%
Revenue beat(8)5
Avg Revenue beat(8)0.4%
Revenue beat(12)6
Avg Revenue beat(12)-3.28%
Revenue beat(16)6
Avg Revenue beat(16)-8.51%
PT rev (1m)1.47%
PT rev (3m)3.8%
EPS NQ rev (1m)0.38%
EPS NQ rev (3m)2.02%
EPS NY rev (1m)0%
EPS NY rev (3m)2.18%
Revenue NQ rev (1m)0.13%
Revenue NQ rev (3m)2.54%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)2.16%
Valuation
Industry RankSector Rank
PE 18.48
Fwd PE 16.72
P/S 5.1
P/FCF 24.9
P/OCF 20.06
P/B 5.89
P/tB N/A
EV/EBITDA 15.43
EPS(TTM)8.94
EY5.41%
EPS(NY)9.88
Fwd EY5.98%
FCF(TTM)6.64
FCFY4.02%
OCF(TTM)8.24
OCFY4.99%
SpS32.42
BVpS28.07
TBVpS-6.97
PEG (NY)1.89
PEG (5Y)6.48
Graham Number75.15
Profitability
Industry RankSector Rank
ROA 11.72%
ROE 28.88%
ROCE 16.73%
ROIC 13.62%
ROICexc 15.61%
ROICexgc 65.14%
OM 25.69%
PM (TTM) 25%
GM 67.97%
FCFM 20.47%
ROA(3y)12.79%
ROA(5y)11.65%
ROE(3y)31.38%
ROE(5y)29.12%
ROIC(3y)15.41%
ROIC(5y)14.48%
ROICexc(3y)18.76%
ROICexc(5y)17.88%
ROICexgc(3y)74.12%
ROICexgc(5y)78.04%
ROCE(3y)18.6%
ROCE(5y)17.28%
ROICexgc growth 3Y1.2%
ROICexgc growth 5Y-0.66%
ROICexc growth 3Y3.58%
ROICexc growth 5Y3.41%
OM growth 3Y0.33%
OM growth 5Y3.14%
PM growth 3Y-15.79%
PM growth 5Y-2.98%
GM growth 3Y-0.56%
GM growth 5Y0.76%
F-Score4
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF 2.74
Debt/EBITDA 1.55
Cap/Depr 60.06%
Cap/Sales 4.94%
Interest Coverage 250
Cash Conversion 74.91%
Profit Quality 81.85%
Current Ratio 1.01
Quick Ratio 0.76
Altman-Z 4.48
F-Score4
WACC9.14%
ROIC/WACC1.49
Cap/Depr(3y)59.5%
Cap/Depr(5y)54.84%
Cap/Sales(3y)5.11%
Cap/Sales(5y)4.8%
Profit Quality(3y)96.25%
Profit Quality(5y)104.12%
High Growth Momentum
Growth
EPS 1Y (TTM)1.37%
EPS 3Y0.64%
EPS 5Y2.85%
EPS Q2Q%15.7%
EPS Next Y9.8%
EPS Next 2Y7.17%
EPS Next 3Y6.91%
EPS Next 5Y6.91%
Revenue 1Y (TTM)5.08%
Revenue growth 3Y4.1%
Revenue growth 5Y1.6%
Sales Q2Q%6.77%
Revenue Next Year5.23%
Revenue Next 2Y4.92%
Revenue Next 3Y4.88%
Revenue Next 5Y4.82%
EBIT growth 1Y-6.56%
EBIT growth 3Y4.44%
EBIT growth 5Y4.79%
EBIT Next Year28.57%
EBIT Next 3Y12.7%
EBIT Next 5Y8.43%
FCF growth 1Y27.51%
FCF growth 3Y0.14%
FCF growth 5Y-0.08%
OCF growth 1Y20.74%
OCF growth 3Y1.2%
OCF growth 5Y0.72%